Mylan is proud to be at the forefront of the fight against HIV/AIDS, a global epidemic that has caused an estimated 39 million deaths and devastated countless lives and communities.
From our manufacturing facilities in India, we supply a comprehensive ARV portfolio of 14 active pharmaceutical ingredients (API) and 50 finished dosage forms in first-line, second-line and pediatric formulations to an estimated 6.4 million men, women and children living with the disease in more than 100 countries. And we look forward to helping achieve the UNAIDS goal of reaching 26 million more people.
We are the world’s largest producer of ARVs, and nearly 50% of people receiving treatment today for HIV/AIDS in the developing world depend on one of our products. We also are a leading supplier of ARV APIs.
In 2012, Mylan launch its domestic business in India its ARV portfolio to help meet the needs of the 2.5 million people living in India with HIV/AIDS – the world’s third largest population of people with the disease.
Over the past decade we have innovated relentlessly. We helped pioneer, for instance, a revolution in pediatric ARV treatment by introducing oral solid dosage forms of combination drugs and developing taste-masked, dispersible forms. As a result, today we supply the majority of pediatric AIDS medicines in the world.
We were the first to market heat-stable formulations of second-line medicines for adult patients who develop resistance to initial ARVs.
And we brought the best-in-class, first-line triple therapy to low-income countries three years before any other generic supplier and only three years after the branded product launched in the U.S. As noteworthy, during that period, and in the absence of competition, we brought prices down on the product by 50%. Today, we sell it for $120 annually, one half of 1% of its price in the U.S.
We continue to invest in additional capacity to help expand access:
- Approximately 50% of our API production capacity is dedicated to ARVs
- We are adding capacity to produce ARV triple therapy for up to 9 million people
- Since 2011, we have made capital expenditures of $250 million to increase our ARV capacity
Our progress in combating HIV/AIDS is also reflected in the powerful partnerships we have with a wide variety of organizations that share our humanitarian goals.
Organizations include the Clinton Health Access Initiative; UNITAID; UNICEF; the Bill & Melinda Gates Foundation; Global Fund to Fight Aids, Tuberculosis and Malaria; the World Health Organization; and the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR.
In addition, our licensing arrangements with Bristol Myers Squibb, Gilead Sciences, Merck, Janssen, MSD and ViiV Healthcare allow us to produce and market generic versions of many of their ARV therapies. We also sponsor clinical research, for instance, to prove the effectiveness of wide-scale treatment in preventing HIV.